Article

ASRS 2019 Street Team: Peter K. Kaiser, MD

Author(s):

OT Staff Reports
Conferences|ASRS

Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD. 

Peter K. Kaiser, MD, shares the take-home message of his presentation, "Safety and Efficacy of Risuteganib in Intermediate Nonexudative Age-Related Macular Degeneration: First Time Results From a Phase 2 Study." Dr. Kaiser presented at the 2019 annual meeting of the American Society of Retina Specialists.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
Related Content
Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe
December 30th 2024

Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery
Published: December 26th 2024 | Updated: December 26th 2024

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Advanced therapies for retinal vascular diseases
December 23rd 2024

Advanced therapies for retinal vascular diseases

Mental health and awareness gaps hinder diabetic eye screenings
December 23rd 2024

Mental health and awareness gaps hinder diabetic eye screenings

© 2025 MJH Life Sciences

All rights reserved.